ProPhet

AI-driven Drug Discovery

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in July 2024 by Tom Shani, Avital Sharir-Ivry, and Amitai Mordechai, ProPhet operates with 1–10 employees. The company has raised $1M across one funding round from 4 investors. In July 2024, ProPhet secured its Pre-Seed funding round.

Business overview

ProPhet is an AI-driven company focused on transforming small molecule drug discovery, particularly for proteins that are challenging to target using conventional methods. The company develops advanced technology that leverages artificial intelligence and machine learning to accelerate and enhance the early stages of drug discovery. By predicting protein dynamics and their interactions with drug candidates, ProPhet aims to rapidly identify promising molecules, addressing unmet needs in the pharmaceutical industry by enabling the targeting of previously "undruggable" proteins. Its platform offers faster, more efficient, and cost-effective solutions compared to traditional and other AI-based methods, serving pharmaceutical companies and researchers globally.

Strategic signal

In October 2024, ProPhet was highlighted in news regarding the transformative potential of AI in drug discovery, specifically noting its launch by AION Labs to accelerate the identification of active small molecules. This signals a strong market validation for ProPhet's AI-driven approach and its strategic importance in advancing pharmaceutical research, suggesting a forward trajectory focused on innovation and efficiency in drug development.

Company Intelligence Q&A

When was ProPhet founded?
ProPhet was founded in July 2024.
Who are the founders of ProPhet?
The founders of ProPhet are Tom Shani, Avital Sharir-Ivry, and Amitai Mordechai.
What is ProPhet's primary focus?
ProPhet focuses on AI-driven small molecule drug discovery, particularly for proteins that are difficult to target with competitive methods.
What was a significant development for ProPhet in October 2024?
In October 2024, ProPhet was featured in news reports highlighting the impact of AI on drug discovery, specifically noting its launch by AION Labs to accelerate the identification of active small molecules.
Which investors participated in ProPhet's Pre-Seed funding round?
In July 2024, ProPhet secured Pre-Seed funding from investors including Merck and AION Labs.

External links